Skip to main content
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. — Investor Relations & Filings

Ticker · APVO ISIN · US03835L2079 LEI · 529900UTQOXOZBMZFN24 US Professional, scientific and technical activities
Filings indexed 683 across all filing types
Latest filing 2025-11-12 Director's Dealing
Country US United States of America
Listing US APVO

About Aptevo Therapeutics Inc.

https://aptevotherapeutics.com/

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-11-12 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Regulatory Filings
2025-11-06 English
8-K
Regulatory Filings
2025-10-30 English
S-1
Regulatory Filings
2025-10-01 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-09-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.